Foghorn Therapeutics (FHTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andres Y. Maldonado from H.C. Wainwright maintained a Buy rating on the stock and has a $13.00 price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Andres Y. Maldonado has given his Buy rating due to a combination of factors that highlight Foghorn Therapeutics’ innovative approach and promising clinical developments. The company’s lead candidate, FHD-909, is a first-in-class oral selective SMARCA2 inhibitor that has shown significant potential in preclinical studies, particularly for treating non-small cell lung cancer (NSCLC) with SMARCA4 mutations. The data presented at the AACR 2025 conference demonstrated robust tumor regression in various NSCLC models, underscoring the drug’s targeted efficacy.
Additionally, Foghorn’s strategic exploration of combination therapies with FHD-909, including its synergy with standard treatments like platinum-based chemotherapies and checkpoint inhibitors, further strengthens its clinical prospects. Beyond FHD-909, Foghorn’s pipeline includes promising programs like the CBP degrader and selective EP300 degrader, which have shown potential in preclinical models for various cancers. These advancements, coupled with the company’s innovative approach to targeting synthetic lethal relationships in oncology, provide a strong basis for the Buy rating.
In another report released today, JMP Securities also maintained a Buy rating on the stock with a $9.00 price target.